MX2020002711A - Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. - Google Patents

Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.

Info

Publication number
MX2020002711A
MX2020002711A MX2020002711A MX2020002711A MX2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A MX 2020002711 A MX2020002711 A MX 2020002711A
Authority
MX
Mexico
Prior art keywords
dimethylimidazo
diazaspiro
octan
pyridazin
pyrido
Prior art date
Application number
MX2020002711A
Other languages
English (en)
Inventor
Serena Maria Fantasia
Christophe Pfleger
Daniel Vincent Fishlock
Fabienne Hoffmann-Emery
Jean-Michel Adam
Gerard Moine
Christian Moessner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2020002711A publication Critical patent/MX2020002711A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/38—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals
    • B01J23/40—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of noble metals of the platinum group metals
    • B01J23/44—Palladium
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J23/00—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00
    • B01J23/70—Catalysts comprising metals or metal oxides or hydroxides, not provided for in group B01J21/00 of the iron group metals or copper
    • B01J23/74—Iron group metals
    • B01J23/755—Nickel
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Catalysts (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)

Abstract

La presente invención se refiere a un proceso para la preparación de derivados de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-(2,8-dimetili midazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4-ona útiles como compuestos farmacéuticamente activos.
MX2020002711A 2017-09-22 2018-09-19 Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona. MX2020002711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17192711 2017-09-22
PCT/EP2018/075282 WO2019057740A1 (en) 2017-09-22 2018-09-19 PROCESS FOR THE PREPARATION OF 7- (4,7-DIAZASPIRO [2.5] OCTAN-7-YL) -2- (2,8-DIMETHYLIMIDAZO [1,2-B] PYRIDAZIN-6-YL) PYRIDO [1,2-DERIVATIVES] ] pyrimidin-4-ONE

Publications (1)

Publication Number Publication Date
MX2020002711A true MX2020002711A (es) 2020-07-20

Family

ID=59955477

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020002711A MX2020002711A (es) 2017-09-22 2018-09-19 Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.

Country Status (14)

Country Link
US (1) US11390632B2 (es)
EP (1) EP3684766A1 (es)
JP (2) JP7075484B2 (es)
KR (2) KR20200058468A (es)
CN (2) CN116813648A (es)
AR (1) AR112828A1 (es)
AU (1) AU2018337597B2 (es)
BR (1) BR112020005549A2 (es)
CA (1) CA3075968C (es)
IL (1) IL273268B2 (es)
MX (1) MX2020002711A (es)
SG (1) SG11202002610TA (es)
TW (1) TWI812646B (es)
WO (1) WO2019057740A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020079203A1 (en) * 2018-10-19 2020-04-23 F. Hoffmann-La Roche Ag New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
JP2024510487A (ja) 2021-03-17 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
CN116981674A (zh) 2021-03-17 2023-10-31 豪夫迈·罗氏有限公司 新的噻唑并嘧啶酮衍生物
EP4308578A2 (en) 2021-03-18 2024-01-24 F. Hoffmann-La Roche AG Process for preparing risdiplam
WO2023170115A1 (en) 2022-03-10 2023-09-14 F. Hoffmann-La Roche Ag Pyrido[1,2-a]pyrimidin-4-one derivatives
WO2024003798A1 (en) * 2022-06-29 2024-01-04 Biophore India Pharmaceuticals Pvt. Ltd. A novel process for the preparation of 7 (4, 7- diazaspiro [2.5] octan-7-yl)-2-(2,8 dimethylimidazo[1,2-b] pyrid azin-6- yl) pyrido-4h-[1,2-a] pyrimidin-4-one with novel intermediates
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
WO2024154148A1 (en) * 2023-01-21 2024-07-25 Harman Finochem Limited Process for preparation of risdiplam, novel intermediates, and process for preparation thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2861609C (en) 2011-12-30 2021-02-16 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
PE20142364A1 (es) * 2012-02-10 2015-01-10 Hoffmann La Roche Compuestos para tratar atrofia muscular espinal
ES2761423T3 (es) * 2014-05-15 2020-05-19 Hoffmann La Roche Compuestos para tratar la atrofia muscular espinal
CN105111201B (zh) * 2014-10-16 2017-01-11 上海页岩科技有限公司 5-甲基-2-(吡啶-2-基氨基)-8H-吡啶并[2,3-d]嘧啶-7-酮化合物
CN108137601A (zh) * 2015-11-12 2018-06-08 豪夫迈·罗氏有限公司 用于治疗肌萎缩性侧索硬化症的化合物
WO2017080967A1 (en) * 2015-11-12 2017-05-18 F. Hoffmann-La Roche Ag Compositions for treating spinal muscular atrophy

Also Published As

Publication number Publication date
US20200216472A1 (en) 2020-07-09
JP7075484B2 (ja) 2022-05-25
AR112828A1 (es) 2019-12-18
BR112020005549A2 (pt) 2020-10-06
IL273268A (en) 2020-04-30
CN116813648A (zh) 2023-09-29
CA3075968A1 (en) 2019-03-28
KR20230020580A (ko) 2023-02-10
TWI812646B (zh) 2023-08-21
CN111132981A (zh) 2020-05-08
KR102691657B1 (ko) 2024-08-05
AU2018337597A1 (en) 2020-03-26
SG11202002610TA (en) 2020-04-29
AU2018337597B2 (en) 2021-03-25
US20220324881A1 (en) 2022-10-13
IL273268B1 (en) 2023-01-01
IL273268B2 (en) 2023-05-01
JP2020534330A (ja) 2020-11-26
TW201920205A (zh) 2019-06-01
EP3684766A1 (en) 2020-07-29
WO2019057740A1 (en) 2019-03-28
KR20200058468A (ko) 2020-05-27
CA3075968C (en) 2023-04-04
JP7398510B2 (ja) 2023-12-14
US11390632B2 (en) 2022-07-19
CN111132981B (zh) 2023-10-31
JP2022107003A (ja) 2022-07-20

Similar Documents

Publication Publication Date Title
MX2020002711A (es) Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
MX2021004487A (es) Nuevas formas de derivados de pirido[1,2-a]pirimidin-4-ona, su formulacion y su proceso de elaboracion.
WO2013128028A8 (en) Pyrazolo-triazine derivatives as selective cyclin- dependent kinase inhibitors
IL261231B (en) Mcl-1 (r)-4-methyl-3,4-dihydropyrazino[1,2-a]indol-1(2h)-one inhibitors
HUE059274T2 (hu) Imidazo[4,5-d]pirrolo[2,3-b]piridin-származékok mint janus-kinázok inhibitorai
MX352831B (es) Cristales de sal.
EP2580214A4 (en) 8- (SULFONYLARYL) PYRIDO [2,3-D] PYRIMIDIN-7 (8H) -ONES FOR THE TREATMENT OF CNS DISORDERS
IL285311A (en) Imidazo[1,2-f][4,2,1]triazine-4-amine derivatives as tlr7 agonists
WO2011156780A3 (en) 8-(sulfonylbenzyl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders
TWI800696B (zh) 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
WO2014205354A3 (en) Free base crystals
IL268923A (en) History of alicyclic-converted pyrazolo[5,1-a]pyrimidine pharmacological activity
IL267801B1 (en) Process for the preparation of 3-disubstituted 5-amino-h6-thiazolo[5,4-d]pyrimidine-7,2-dione compounds
HUE056561T2 (hu) Gyógyászatilag hatékony aril-szubsztituált pirazolo[1,5-a]pirimidin származékok
IL272988A (en) Imidazo-[1,5-A]pyrazine derivatives as PI3K-delta inhibitors
MX2023004924A (es) Nuevo tratamiento de la atrofia muscular espinal (sma).
MX2023010761A (es) Proceso para preparar risdiplam.
MX2018001350A (es) Procesos para preparar un inhibidor de fgfr.
EP4065581C0 (en) PROCESS FOR THE PREPARATION OF (9S)-2-BROMO-9-(2,3,4-TRIFLUOROPHENYL)-6,7,8,9-TETRAHYDRO-5H-[1,2,4]TRIAZOLO[1,5-A]AZEPINE
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
WO2015145333A8 (en) Process for the preparation of sitagliptin and its intermediate
EP3931197C0 (en) PROCESS FOR THE PREPARATION OF (6S)-3-[(4S)-4-CYANO-2-OXO-PYRROLIDIN-1-YL]-6-METHYL-N-(3,4,5-TRIFLUOROPHENYL)-6,7- DIHYDRO-4 H-PYRAZOLO [1,5-A] PYRAZINE-5-CARBOXAMIDE
WO2017144973A3 (es) Formulaciones farmacéuticas novedosas que comprenden un inhibidor de pds5
MX2016007494A (es) Tratamiento de la esclerosis multiple con un derivado de 1,2,4-triazolo [1,5-a] piridina.